ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 23rd
Annual Healthcare Conference
WALTHAM, Mass. -- December 06, 2012
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP) technology
and antibody expertise, today announced that Daniel Junius, President and CEO,
will present at the upcoming Oppenheimer 23^rd Annual Healthcare Conference in
New York. The presentation is scheduled for 10:00 am ET on December 13, 2012.
The webcast of this presentation can be accessed live through the “Investor
Information” section of the Company’s website, www.immunogen.com; a replay of
the presentation will be available at the same location for one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its TAP
technology together with the Company’s expertise in monoclonal antibodies and
tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to
deliver one of ImmunoGen's purpose-developed cancer-killing agents
specifically to tumor cells. Ten TAP compounds are now in clinical testing, of
which three are wholly owned by the Company. Marketing applications for
trastuzumab emtansine (T-DM1), the most advanced compound using ImmunoGen's
TAP technology, are under review in the US and Europe. Roche is developing
this compound globally under an agreement between ImmunoGen and Genentech, a
member of the Roche Group. More information about ImmunoGen can be found at
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Press spacebar to pause and continue. Press esc to stop.